Definitions and burden of heart failure {#Sec1}
=======================================

The term \'heart failure\' (HF) is used to describe a condition wherein cardiac output is insufficient to meet metabolic requirements \[[@CR1]\]. Clinically, it is defined as a syndrome where patients have typical signs and symptoms resulting from an abnormality of cardiac structure or function \[[@CR2]\]. Contemporary terminology used to describe HF is based on left ventricular ejection fraction (EF). This is considered important not only because of prognosis (the lower the EF the poorer the survival) but also because the major trials that inform the evidence base have almost exclusively focussed on patients who have HF with reduced ejection fraction (HF-REF) \[[@CR2]\]. A subgroup of patients also present with classical signs and symptoms but in the context of preserved ejection fraction (HF-PEF). These patients often have evidence of diastolic dysfunction and this is considered by many as the cause of HF symptoms.

It is estimated that 1 to 2% of the adult population in developed countries have HF with the prevalence increasing to ≥10% among patients aged over 70 years; more than half of these patients have HF-REF \[[@CR3]\]. The most common underlying aetiology in HF-REF is coronary artery disease (CAD) resulting in myocardial damage. Other common causes include hypertension, valvular pathology, viral infection and alcohol excess \[[@CR2]\]. HF-PEF is more common in older, female patients. It is less frequently due to CAD and more often linked to hypertension and atrial fibrillation (AF), with the diagnosis being one of exclusion of other non-cardiac causes of breathlessness \[[@CR2]\].

HF admissions account for 5% of all medical admissions (making it the commonest cause of unscheduled admission in older adults) and 2% of the total UK National Health Service budget \[[@CR4]\]. Societal and demographic changes, including aging of the general population and improved survival from CAD, will increase HF prevalence (Figure [1](#Fig1){ref-type="fig"}) with a potential doubling in HF prevalence within the next 40 years \[[@CR2]\].Figure 1**Incidence of heart failure within the Framingham cohort and prevalence of dementia by age and sex (pooled from five centres of the Medical Research Council cognitive function and ageing study)**. Authors' own figure based on data from \[[@CR5]\]. HF, heart failure.

Heart failure and cognitive impairment -- strength of association {#Sec2}
=================================================================

The co-existence of symptomatic \'heart failure\' and \'brain failure\' has been recognised for decades, with a description of \'cardiogenic dementia\' first introduced in the 1970s. While the co-occurrence of HF and cognitive problems will be familiar to most clinicians, the topic has received relatively little research interest compared with other aspects of cardiac disease. In collating and offering a synthesis of the available literature describing the association of HF and cognition, we have found a disparate and inconsistent literature, characterised by small sample sizes, heterogeneity and multiple potential biases. We provide a brief narrative overview of the field and have tabulated a more detailed summary of findings from available cross-sectional and prospective studies (Tables [1](#Tab1){ref-type="table"} to [3](#Tab3){ref-type="table"}).Table 1**Studies examining the prevalence of cognitive impairment in patients with heart failureStudySamplePopulationMedian age in years (SD)Study methodologyInclusion criteriaExclusion criteriaCV measures/criteriaCognitive assessment tool(s) usedResults**Zuccalà 1997 \[[@CR6]\]57 HF ptsConsecutive admissions to hospital77Cross-sectionalNot specifiedCo-morbid psychiatric or physical illness and previous diagnosis of CILVEF (mean EF 45%)\
NYHA II-IIIMMSE, MDBandRCPM53% of HF pts showed global CI with MMSE less than 24Callegari 2002 \[[@CR7]\]64 HF pts, 321 healthy controlsAge \<65 years and consecutive admissions to hospital52 (8)Cross-sectionalNot specifiedCo-morbid psychiatric or neurological illness. Previous diagnosis of CI and female sexLVEF \<50%Multidomain neuropsychiatric batteryHF pts scored lower than control group in short-term verbal memory, short-term visuospatial memory and visual spatial logical abilityNYHA I-IIICardiopulmonary testing with treadmillRight heart catheterisationTrojano 2003 \[[@CR8]\]149 HF NYHA II ptsAge \>65 years and consecutive admissions to hospitalHF NYHA II: 75 (7)Cross-sectionalNot specifiedCo-morbid psychiatric, neurological or physical illness. Previous diagnosis of CINo measure of LV functionMultidomain neuropsychiatric batteryHF pts scored worse than those without HF in domains of: attention, verbal fluency, verbal learning159 HF NYHA III/IVHF NYHA III/IV: 77 (7)NYHA II-IVNo significant difference between pts with moderate or severe HF207 non-HF controlsNon-HF controls: 74 (7)Zuccalà 2005 \[[@CR9]\]1,511 HF pts, 11,790 control patientsAll geriatric or general medical hospital admissions79 (9)Cross-sectionalNot specifiedNot specifiedHF diagnosis based on discharge documentationHodkinson abbreviated mental test35% of HF pts showed global CI\
29% of non-HF pts showed global CIFeola 2007 \[[@CR10]\]60 HF-REFConsecutive admissions to hospital66Cross-sectionalHF-REF: clinical HF, NYHA II-IV, LVEF ≤50%Not specifiedLVEFMultidomain neuropsychiatric battery23% of HF pts showed global CI12 HF-PEFHF-PEF: diagnosed based on E/A ratio, deceleration time and LV dilatationNYHA II-IVBNPDebette 2007 \[[@CR11]\]83 HF ptsConsecutive admissions to hospital62Cross-sectionalNot specifiedHearing/visual impairmentLVEF \<45%MMSE61% of HF pts showed global CINYHA I-IVDodson 2013 \[[@CR12]\]282 decompensated HF ptsAge \>65 years and non-consecutive admissions to hospital80 (8)ProspectiveEnglish speakingCo-morbid psychiatric illnessHF diagnosis based on documentation in medical recordsMMSE25% of HF pts showed evidence of mild CI 22% of HF pts showed moderate to severe CISchmidt 1991 \[[@CR13]\]20 iDCM ptsAge \<50 years and ambulatory outpatients onlyiDCM: 38 (5)Cross-sectionalNot specifiedCo-morbid psychiatric, neurological or physical illnessLVEF 14-45%LGT-3 and ALIDSystolic HF pts performed worse than the control group in domains of attention, learning and memory and reaction time20 healthy controlsHealthy controls: 41 (8)NYHA II-IVGrubb 2000 \[[@CR14]\]20 HF pts with CADsAmbulatory outpatients onlyHF: 68Cross-sectionalNot specifiedCo-morbid psychiatric or neurological illness. Previous hospital admission within 6 monthsHF: LVEF \<40%, NYHA III/IVRBMT and WMSNo difference between HF pts and control group20 CAD controlCAD controls: 67CAD controls: LVEF \>55%, no CHFRiegel 2002 \[[@CR15]\]42 HF ptsAmbulatory outpatients only75 (12)Cross-sectionalEnglish speakingCo-morbid physical or psychiatric illnessNo measure of LV functionMMSE and CIMS29% of HF pts showed evidence of global CINYHA I-IVVogels 2007 \[[@CR16]\]62 HF ptsAge \>50 years and ambulatory outpatients onlyHF: 69 (9))Case controlHF pts: diagnosis of HF \>6 months and stable on medication \>4 weeksCo-morbid physical, neurological or psychiatric illness. Previous diagnosis of CILVEF \<40%Multidomain neuropsychiatric batteryHF pts scored lower than the healthy control group in all domains53 CAD controlsCAD controls: 69 (10)CAD controls: IHD but no clinical CHF and EF \>40%NYHA II-IVHF pts scored lower than the IHD control group in domains of memory and mental speed42 healthy controlsHealthy controls: 67 (9IHD control group scored lower than the healthy control group in language onlyHoth 2008 \[[@CR17]\]31 HF ptsAge \>55 years and ambulatory outpatients onlyHF: 69 (9)Cross-sectionalEnglish speakingCo-morbid physical, neurological or psychiatric illness. Previous diagnosis of CILVEF \<40%Multidomain neuropsychiatric batterySystolic HF pts scored lower than the IHD control group in domains of executive function and cognitive flexibility31 CAD controlsCAD controls: 69 (9)Minimum of 8th grade educationNYHA II-IVCAD controls: angina/previous MI/PCI/PVD and HF excluded on basis of clinical examinationBeer 2009 \[[@CR18]\]31 HF ptsAmbulatory outpatients onlyHF: 54 (11)Case controlNot specifiedCo-morbid neurological illness or previous diagnosis of CILVEF \<40%Block design, CVLT and \'F,A,S test\'Systolic HF pts scored lower than control group in all cognitive domains24 healthy controlsHealthy controls: 56 (8)NYHA IILWHFQStanek 2009 \[[@CR19]\]40 HF pts, 35 CAD controlsAmbulatory outpatients only70 (8)ProspectiveEnglish speakingCo-morbid psychiatric or neurological illness. Previous diagnosis of CINYHA II-IIIDRSNo difference between systolic HF pts and CAD control patients in all domainsCAD controls: history of MI, CAD, cardiac surgery, hypertensionCO \<4 L/minute on echoSauvé 2009 \[[@CR20]\]50 HF pts\
50 healthy controlsAge \>30 years in HF pts and \>55 years in controls. Ambulatory outpatients onlyHF: 63 (14)\
Healthy controls: 63 (14)Case controlDiagnosis of HF \>6 monthsCo-morbid psychiatric or neurological illnessLVEF ≤40%\
NYHA II-IVMultidomain neuropsychiatric batterySystolic HF pts scored lower than control group in domain of verbal memoryPressler 2010 \[[@CR21]\]249 HF ptsAmbulatory outpatients onlyHF: 63 (15)Cross-sectionalHF: LVEF ≤40% and clinical HFCo-morbid psychiatric, neurological or physical illness. Previous diagnosis of CINYHAMultidomain neuropsychiatric batteryHF group performed worse than healthy and general medical groups in domains of memory, executive function and psychomotor speed63 healthy controlsHealthy controls: 53 (17)Healthy controls: absence of any medical condition or controlled CV risk factorsLVEF102 general medical ptsMedical group: 63 (12)Medical group: major chronic disorder other than HFBauer 2012 \[[@CR22]\]51 HF-REF, 29 HF-PEFAge \>21 years and ambulatory outpatients only72 (12)Cross-sectionalHF-REF: history of HF-REF \>6 months, stable on medication \>4 weeks, LVEF ≤40%Co-morbid psychiatric, neurological or physical illness. Previous diagnosis of CILVEFMultidomain neuropsychiatric batteryHF-REF and HF-PEF pts performed worse than age- and educated-adjusted healthy control groups in executive function, attention, language, memory and psychomotor speedHF-PEF: history of HF-PEF \>6 months, stable on medication \>4 weeks, LVEF \>41%NYHAFesta 2011 \[[@CR23]\]169 HF-REF, 38 HF-PEFAge \>17 years and ambulatory outpatients only69RetrospectiveOn medical treatment for HFCo-morbid neurological illnessLVEFMultidomain neuropsychiatric batteryLow EF was associated with poor memory in pts over 63 years oldHaemodynamically stablePts \<63 years old had preserved memory function regardless of EF.Not receiving mechanical circulatory supportSteinberg 2011 \[[@CR24]\]55 HF ptsAmbulatory outpatients only55 (8)Cross-sectionalStable clinical statusCo-morbid neurological or physical illness. Previous diagnosis of CILVEF ≤45%Multidomain neuropsychiatric battery44% of HF pts showed evidence of global CINYHA I-III6 minute walk testJefferson 2011 \[[@CR25]\]1,114 pts from Framingham Heart StudyAge \>40 and \<89 years and ambulatory outpatients only67 (9)Cross-sectionalNot specifiedCo-morbid neurological illness or previous diagnosis of CILVEFMultidomain neuropsychiatric batteryU-shaped association between LVEF and cognitive performanceCardiac MRIMiller 2012 \[[@CR26]\]140 HF ptsAge \>50 and \<85 years and ambulatory outpatients only69 (9)Cross-sectionalEnglish speakingCo-morbid psychiatric or neurological illnessNo measure of LV functionMultidomain neuropsychiatric battery62% of HF pts showed evidence of global CINo NYHA classification2 minute step testAlmeida 2012 \[[@CR27]\]35 HF ptsAge \>45 years and ambulatory outpatients onlyHF: 69 (9)Cross-sectionalHF: EF \<40%, clinical HF ≥6 months, English speaking, NYHA I-IIICo-morbid psychiatric, neurological or physical illness. Previous diagnosis of CILVEFMultidomain neuropsychiatric batteryHF pts scored lower than the healthy control group in domains of immediate/long-term memory and psychomotor speed56 CAD controlsCAD controls: 67 (10)CAD controls: previous MI, English speaking, EF ≥60%, no clinical HFNYHANo difference between the HF group and IHD control group in cognition64 healthy controlsHealthy controls: 69 (11)Healthy controls: English speaking, no previous MI/angina, EF ≥60%Hawkins 2012 \[[@CR28]\]251 HF ptsAmbulatory outpatients only66 (10)Cross-sectionalEnglish speakingCo-morbid psychiatric illness. Previous diagnosis of CILVEF ≤40%Multidomain neuropsychiatric battery58% of HF pts had CI with poor scores in the domains of verbal learning and verbal memoryBratzke-Bauer 2013 \[[@CR29]\]47 HF-REFAge \>50 years and ambulatory outpatients onlyHF-REF: 75 (9)Cross-sectionalHistory of HF \>6 monthsCo-morbid psychiatric, neurological or physical illness. Previous diagnosis of CILVEFMultidomain neuropsychiatric battery23% of the HF-REF cohort showed evidence of CI33 HF-PEFHF-PEF: 68 (15)Stable on medication ≥4 weeksNYHA3% of the HF-PEF cohort showed evidence of CIHF-PEF based on AHA criteriaHuijts 2013 \[[@CR30]\]491 HF-REFAge \>60 years and ambulatory outpatients only77 (8)ProspectiveHF-REF: hospitalization within past yearCo-morbid physical illnessHF-REF: LVEF \<45%, NYHA II-IV, NT-proBNP \>400 pg/mlAMT8% of HF-REF group showed evidence of severe CI (AMT ≤7)120 HF-PEFHF-PEF: NT-proBNP ≥400 pg/ml if pt \<75 years or ≥800 pg/ml if pt ≥75 yearsHF-PEF: LVEF ≥45%13% of HF-PEF group showed evidence of severe CI (AMT ≤7)Kindermann 2012 \[[@CR31]\]20 decompensated HF ptsDecompensated HF: non-consecutive admissions to hospitalDecompensated HF: 60 (16)ProspectiveDecompensated HF: caused by ischaemic or DCM, symptomatic HF for ≥6 months, clinical signs of decompensation, for example, raised JVPCo-morbid psychiatric, neurological or physical illness. Previous diagnosis of CILVEF \<45%Multidomain neuropsychiatric batteryDecompensated HF group scored lower than stable HF group in domains of memory, executive control and processing speed20 stable HF ptsStable HF: outpatientsStable HF: 61 (17)Stable HF pts: CHF of ischaemic or DCM, NYHA III-IV, no clinical signs/history of decompensation for ≥3 monthsNYHA III/IVStable HF group scored lower than the healthy control group in domains of intelligence and episodic memory20 healthy controlsHealthy controls: 62 (15)AHA, American Heart Association; ALID, adjective list of Janke and Debus; AMT, Abbreviated Mental Test; BNP, brain natriuretic peptide; CAD, coronary artery disease; CHF, congestive heart failure; CI, cognitive impairment; CIMS, complex ideational material subset; CO, cardiac output; CV, cardiovascular; CVLT, California Verbal Learning Test; DCM, dilated cardiomyopathy; DRS, Disability Rating Scale; E/A ratio, ratio of mitral peak velocity of early filling (E) to mitral peak velocity of late filling (A); EF, ejection fraction; HF, heart failure; HF-REF, heart failure-reduced ejection fraction; HF-PEF, heart failure-preserved ejection fraction; iDCM, idiopathic dilated cardiomyopathy; IHD, ischaemic heart disease; JVP, jugular venous pressure; LGT-3, Lern und Gedachtnistest; LV, left ventricular; LVEF, left ventricular ejection fraction; LWHFQ, Living With Heart Failure Questionnaire; MDB, mental deterioration battery; MI, myocardial infarction; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging; NT-pro BNP, N-terminal prohormone brain natriuretic peptide; NYHA, New York Heart Association; pts, patients; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; RBMT, Rivermead Behavioural Memory Test; RCPM, raven coloured progressive matrices; SD, standard deviation; WMS, Weschler Memory Scale.Table 2**Studies examining cognitive changes over time in the heart failure populationStudySamplePopulationMedian age in years (SD)Study methodologyInclusion criteriaExclusion criteriaCV measuresCognitive assessment tool usedFollow-up periodResults**Karlsson 2005 \[[@CR32]\]146 CHF ptsAge \>60 years and outpatients76 (8)ProspectiveEF \<45%Co-morbid psychiatric, neurological or physical illness. Previous diagnosis of CILVEFMMSE6 months12% of HF patients had MMSE scores \<24 at baselineNYHA II-IVNYHAAnd 4% had MMSE scores \<24 at 6 monthsTanne 2005 \[[@CR33]\]20 CHF underwent exercise programme\
5 CHF pts as control ptsOutpatients63 (13)ProspectiveEF ≤35%Co-morbid psychiatric, neurological or physical illnessLVEFMultidomain neuropsychiatric battery18 weeksImprovement in executive function post-exercise programmeNYHA IIINYHAHistory of HF for ≥6 monthsMod-Bruce ETTNo change in cognition in control group with timeStable on medication ≥6 weeks6 minute walk testStanek 2009 \[[@CR19]\]40 HF pts, 35 CAD controlsAge \>53 and \<84 years. Outpatients70 (8)ProspectiveHF: English speakingCo-morbid psychiatric or neurological illness. Previous diagnosis of CINYHADRS12 monthsHF patients improved at 12 months, particularly in attentionNYHA II or IIICO \<4 L/minuteCOCardiac controls stable at 12 monthsCAD controls: CO ≥4 L/minute, history of MI/CADAlmeida 2013 \[[@CR34]\]77 HF ptsAge \>45 years and outpatientsHF: 68 (10)ProspectiveHF: EF \<40%, English speakingCo-morbid psychiatric or neurological illness. Previous diagnosis of CINYHAMultidomain neuropsychiatric battery2 yearsCHF group showed cognitive decline compared with CAD and healthy controls73 CAD controlsCAD controls: 68 (10)CAD controls: previous MI and EF \>60%, English speakingLVEF81 healthy controlsHealthy controls: 69 (11)Healthy controls: no history of CAD, English speaking6 minute walk testHjelm 2011 \[[@CR35]\]95 HF pts\
607 non-CHF controlsAge \>80 years and outpatients84 (3)ProspectiveNot specifiedNot specifiedHF diagnosis based on documentation in medical recordsMultidomain neuropsychiatric battery10 yearsHF patients showed significant decline in episodic memory and spatial performance compared with controlsRiegel 2012 \[[@CR36]\]279 consecutive HF pts (HF-REF and HF-PEF)Age \<80 years and outpatients62 (12)ProspectiveStage C HF and English speakingCo-morbid psychiatric or physical illness. Previous diagnosis of CINYHA I-IVMultidomain neuropsychiatric battery6 monthsNo significant change in cognition over 6 months (HF-REF and HF-PEF)LVEFMinimal improvement in DSST in both groups (likely due to learned effect)Higher LVEF associated with lower DSST scoreHuijts 2013 \[[@CR30]\]491 HF-REF\
120 HF-PEFAge \>60 years and outpatients77 (8)ProspectiveHF-REF: hospitalization within past yearCo-morbid physical illnessHF-REF: LVEF \<45%, NYHA II-IV, NT-proBNP \>400 pg/mlAMT18 monthsHF-REF: 23% of HF pts showed decline of ≥1 point in AMT over 18 monthsHF-PEF: NT-proBNP ≥400 pg/ml if pt \<75 years or ≥800 pg/ml if pt ≥75 years120 HF-PEF: LVEF ≥45%HF-PEF: 24% of HF pts showed improvement of ≥1 point in AMT over 18 monthsAMT, Abbreviated Mental Test; CAD, coronary artery disease; CHF, congestive heart failure; CI, cognitive impairment; CO, cardiac output; CV, cardiovascular; DRS, Disability Rating Scale; DSST, digit symbol substitution test; EF, ejection fraction; ETT, exercise tolerance test; HF, heart failure; HF-REF, heart failure-reduced ejection fraction; HF-PEF, heart failure-preserved ejection fraction; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MMSE, Mini-Mental State Examination; NT-pro BNP, N-terminal prohormone brain natriuretic peptide; NYHA, New York Heart Association; pts, patients; SD, standard deviation.Table 3**Studies examining the relationship between cognitive impairment and outcomes in patients with heart failureStudySamplePopulationMedian age in years (SD)Study methodologyInclusion criteriaExclusion criteriaMeasuresResults**Zuccalà 2003 \[[@CR37]\]1511 HF pts 11,790 controlsAll geriatric or general medical admissions79 (9)ProspectiveNot specifiedNot specifiedHodkinson abbreviated mental testMean length of hospital stay: pts with CI = 15 ± 10 days; pts without CI = 15 ± 9 daysLength of hospital stayInpatient mortality: pts with CI, 18%; pts without CI, 3%1 year mortality1-year mortality: pts with CI, 27%; pts without CI, 15%Karlsson 2005 \[[@CR32]\]146 CHF ptsAge \>60 years and outpatients76 (8)ProspectiveLVEF \<45%Co-morbid psychiatric, neurological or physical illness. Previous diagnosis of CIHF self-careSelf-care scores were significantly higher in those with MMSE \>24 compared to those ≤24NYHA II--IVquestionnaireMMSERiegel 2007 \[[@CR38]\]29 CHF ptsOutpatients64 (10)Cross-sectionalLVSD on echoCo-morbid psychiatric or physical illness. Previous diagnosis of CISelf-care of HF indexCI was worse in the poor self-care group compared to the good and expert self-care groups but did not reach level of significanceClinical HFDSSTEnglish speakingProbed memory recallCameron 2009 \[[@CR39]\]50 CHF ptsAge \>45 years and consecutive hospital admissions73 (11)Cross-sectionalClinical CHFCo-morbid neurological illness. Previous diagnosis of CISelf-care of HF indexCI was not a predictor of self-careLVSD on echoCardiac depression scaleEnglish speakingMMSECameron 2010 \[[@CR40]\]93 CHF ptsAge \>45 years and consecutive hospital admissions73 (11)Cross-sectionalClinical CHFCo-morbid neurological illness. Previous diagnosis of CISelf-care HF indexCI and self-care management were significantly associated (t = 2.7; *P* \< 0.01)LVSD on echoMMSEEnglish speakingMoCAPulignano 2010 \[[@CR41]\]93 CHF ptsConsecutive outpatients77 (6)Cross-sectionalNot specifiedNot specifiedThe European heart failure self-care behaviour scaleMMSE was negatively correlated with self-care behavioural scores (r = 0.58, *P* \< 0.001)MMSEAlosco 2013 \[[@CR42]\]110 CHF ptsAge \>50 years and \<85 years. Outpatients70 (9)ProspectiveNYHA II-IVCo-morbid psychiatric, neurological or physical illness. Previous diagnosis of CILawton-Brody instrumental activities of daily livingPoorer performance on 3MS was associated with worse total activities of daily living performanceEnglish speakingModified MMSE (3MS)Harkness 2013 \[[@CR43]\]100 CHF ptsAge \>55 years and outpatients72 (10)Cross-sectionalConfirmed HF using the Boston criteriaCo-morbid psychiatric illness or previous diagnosis of CIMoCAMoCA score of \<26 was significantly associated with worse self-care managementLVEF ≤45%Self-care in HF indexChange in symptoms on previous 3 monthsGeriatric Depression ScaleEnglish speakingAlosco 2013 \[[@CR42]\]175 CHF ptsAge \>50 years and \<85 years. Outpatients68 (10)Cross-sectionalNYHA II-IVCo-morbid psychiatric, neurological or physical illness. Previous diagnosis of CILawton-Brody instrumental activities of daily livingPoorer executive function was independently associated with poorer total activities of daily living performanceEnglish speakingExecutive function assessed by FAB and LNSCHF, congestive heart failure; CI, cognitive impairment; DSST, digit symbol substitution test; FAB, frontal assessment battery; HF, heart failure; LNS, letter number sequencing; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment Tool; NYHA, New York Heart Association; SD, standard deviation.

Studies describing cognitive impairment (CI) in HF-REF have estimated prevalence at anywhere between 30 and 80% of patients (Table [1](#Tab1){ref-type="table"}). This heterogeneity results from differences in study designs, case mix and cognitive assessments employed. Accepting the limitations of the evidence, even at the more conservative estimates of prevalence, the literature would suggest that CI frequently co-exists with HF-REF (Table [1](#Tab1){ref-type="table"}).

Cross-sectional studies of cognition in HF have value in quantifying the burden of prevalent disease but give no clues as to temporal relationship or causation. To describe the incidence and \'natural history\' of cognition in HF ideally requires prospective follow-up of a cohort free from CI at inception. Few studies have utilised this design and, where data are available, the validity is limited by small sample sizes, limited follow-up with substantial attrition and use of cognitive assessment tools that may not be sensitive to modest but clinically meaningful change (Table [2](#Tab2){ref-type="table"}). Inherent in this study design is the assumption that CI follows or is a consequence of the HF pathology \[[@CR16]\]. A literature around \'reverse causation\' in heart disease has been described. In brief, early studies describing association of psychological or \'personality\' factors and heart disease assumed that the neuropsychological traits pre-dated and were probably causative in the development of the cardiac condition. Subsequent data have questioned this temporality and suggest that subclinical (undiagnosed) vascular disease may cause psychological distress phenotypes \[[@CR44]\]. Such arguments may also hold for HF and neuropsychological disease, where both cognitive change and psychological distress may be the cause or effect of HF. Investigating reverse causation is challenging but possible; to avoid biases from early mortality, large datasets with sufficient prospective follow-up are required \[[@CR44]\].

Association does not imply causation and we must be mindful that both HF and CI are diseases of older age with many shared pathologies. Recognising this, many HF studies have defined an age-related inclusion criterion. With all the caveats that come with the heterogeneity of the available data, it would seem that association of CI and HF is present at all ages (Table [1](#Tab1){ref-type="table"}). Studies that have attempted more sophisticated adjustment for confounders illustrate the inherent difficulty in teasing out what is contributory to cognitive decline and what is association or epi-phenomenon. In general, HF patients tend to have poorer scores on cognitive tests when compared with a \'healthy\' (no cardiac disease) control group \[[@CR34]\], but this comparator is still potentially confounded by cardiovascular comorbidity in the HF group. Inclusion of a cohort with common vascular risk factors but no HF may allow determination of whether HF *per se* is associated with CI. Where attempts have been made to utilise this design, studies have been modest in size and results contradictory \[[@CR16],[@CR19]\]. Some authors have described little difference between groups and others have described increased rates of CI in HF-REF groups, particularly in \'executive function\' domains.

A direct \'dose response\' relationship between severity of HF and severity of CI would strengthen arguments for a causal link. HF-REF can be quantified in terms of EF or symptom burden. For both measures there is an independent association with increasing prevalence of CI \[[@CR6],[@CR8],[@CR13],[@CR16],[@CR17],[@CR20]\] and the poorest scores on cognitive testing are most often seen in those with the severest disease \[[@CR23]\]. Interestingly, an association with CI is also seen in those with echocardiographic evidence of reduced EF but without symptoms of HF (that is, patients with asymptomatic left ventricular systolic dysfunction) \[[@CR7]\].

Few studies have described cognitive function in patients with HF-PEF \[[@CR10],[@CR22],[@CR23],[@CR29],[@CR30],[@CR45]\], but the pattern seems to be that CI is a substantial problem in all HF regardless of EF. Whether the prevalence or phenotype of cognitive change differs between HF-PEF and HF-REF is not clear as there have been few comparative studies. In keeping with much of the HF and cognition literature, where data are available, there is substantial potential for bias and results are contradictory. Some authors have described higher proportion of cognitive problems in HF-REF \[[@CR29]\], while secondary analyses of clinical trials have suggested either an equal proportion of CI across the groups or an excess of CI in those with HF-PEF \[[@CR30],[@CR45]\].

Heart failure and delirium {#Sec3}
==========================

Two patterns of cognitive problems in HF are recognised: a chronic, progressive decline in cognitive ability and a more acute change in cognition often in association with decompensated disease. The acute delirium and HF relationship has not been well described. Delirium is a common sequela of decompensated HF; one study estimated that 17% of unscheduled HF hospitalisations had features of delirium \[[@CR46]\]. Where delirium accompanies HF, outcomes are generally poor with increased mortality and length of stay \[[@CR46]\]. However, delirium is a frequent complication of most medical emergencies in older adults and the delirium of decompensated HF may be no more or less frequent than the delirium that accompanies other medical conditions such as stroke or pneumonia.

Impact of cognitive impairment in heart failure {#Sec4}
===============================================

There is a literature describing the relationship between CI and \'classical cardiovascular trial\' outcomes (Table [3](#Tab3){ref-type="table"}). In general the presence of CI in HF is associated with poorer clinical outcomes, including longer hospital admissions, increased inpatient mortality and increased 1-year mortality \[[@CR37]\]. However, as CI seems to be associated with more severe HF and with other medical comorbidities, we should not assume that poorer outcomes are directly attributable to the cognitive state. Several other important metrics have been described in HF cohorts and all seem to be worsened by the presence of CI, including functional ability, medication adherence and institutionalisation (Table [3](#Tab3){ref-type="table"}). Cognitive decline tends not to occur in isolation and, as with other diseases of older age, the presence of impaired cognition in HF is often associated with concomitant functional decline and poor levels of self-care \[[@CR32],[@CR37],[@CR38],[@CR40]-[@CR43],[@CR47]\].

Potential pathophysiological explanations of cognitive impairment in heart failure {#Sec5}
==================================================================================

Historically, research describing the pathology of the dementias has been polarised, with vocal proponents for \'amyloid\' and \'cerebral small vessel disease\' aetiologies. Increasingly these processes are recognised as co-existing with complex biological interactions \[[@CR48]\]. The same is likely true of the pathogenesis of CI in HF. Chronic cerebral hypoperfusion and occult cardioembolic disease are exemplar mechanistic explanations that have dominated the literature on cognition in HF. Both processes have face validity, have strong supporting scientific and observational data and yet have traditionally been studied in isolation \[[@CR49]\]. For ease of understanding, we will keep this dichotomy and discuss the potential pathological mechanisms separately; however, it seems likely that both processes frequently coexist in patients with HF and may exert pathological synergy.

Although most of the postulated mechanisms we will discuss have been described in the context of HF-REF, issues of cerebral hypoperfusion, thrombotic disease and concomitant cardiovascular disease are also seen in HF-PEF \[[@CR2]\] and it seems likely they will factor in the pathogenesis of any cognitive decline seen in this syndrome.

Confounding from other diseases {#Sec6}
-------------------------------

Co-existence of dementia and CI has been reported in a variety of cardiovascular disorders, including CAD, myocardial infarction and valvular heart disease. Midlife exposure to the common vascular risk factors of diabetes, hypertension and smoking is associated with later life cognitive decline \[[@CR16]\]. This background is relevant to the study of patients with HF as many have a history of one or more of these co-morbidities. As discussed previously, dissecting the contribution of HF from concomitant vascular risk and disease is challenging but is essential for future studies that wish to describe the cognitive component of HF.

AF is a potential confounding condition worthy of separate discussion. The association of AF with cognitive decline is compelling \[[@CR50]\]. Much of the CI associated with AF will be driven by cardioembolic stroke. However, cognitive decline is also seen in patients with AF and no history of clinical stroke, possibly representing occult embolic disease \[[@CR50]\]. AF is common in HF and prevalence increases with severity of disease. Up to 50% of patients with \'end-stage\' HF have AF \[[@CR51]\]. Increasing use of ambulatory monitors is discovering substantial undetected paroxysmal AF and so these figures may be underestimates. While AF will be a factor in the pathogenesis of some HF-related CI, it is probably not the sole explanation. Where studies have controlled for the presence of AF in their HF patient population, there remains substantial prevalent CI \[[@CR10],[@CR11],[@CR13],[@CR16],[@CR31]\].

Any discussion of cognition in cardiac disease has to consider the effect of invasive and instrumental procedures. The interventional toolkit available to cardiologists is increasingly sophisticated, with new indications emerging. Acute and chronic neurological deficits associated with cardiac surgery are well described \[[@CR52]\] while interventions such as cardiac catheterisation and transcatheter aortic valve replacement have also been associated with post-procedure CI \[[@CR53]\]. The mechanism of neurological insult associated with these procedures is likely a combination of reduced cerebral perfusion and embolic disease.

As well as \'physical\' conditions, mood disorder may also represent an important confounder of association between HF and CI. Clinically important depression and anxiety are common in patients with HF. Depression is found in nearly 30% of HF patients and is associated with poor outcomes \[[@CR54]\]. There is a complex interplay between cognitive decline (particularly in the context of \'small vessel disease\'), mood disorder and systemic vascular disease that is poorly understood but likely to be relevant to HF. Mood disorders are particularly important to detect as they can respond to intervention, making mood disorder in HF a potentially treatable form of cognitive decline.

Shared pathophysiology (systemic inflammation and amyloid) {#Sec7}
----------------------------------------------------------

Several recent studies have demonstrated the formation of tangle and plaque-like structures and fibrillar deposits (that is, the \'hallmark\' lesions of Alzheimer's disease (AD) dementia) within the myocardium of patients with hypertrophic cardiomyopathy and idiopathic dilated cardiomyopathy \[[@CR55]\]. Mis-folded proteins in the form of intermediate oligomers have also been described in cardiac tissue, with a distribution similar to that observed in the brain of patients with AD \[[@CR55]\], raising the possibility of a common myocardial and cerebral pathology in a subset of patients with HF.

The systemic inflammatory state recognised in patients with HF may also contribute to CI \[[@CR56]\]. It is postulated that inflammatory mediators influence cognition via diverse cytokine-mediated interactions between neurons and glial cells. *In vitro* and animal models support the inflammation and cognitive decline hypothesis and studies in humans with HF are emerging, although data are far from definitive at present \[[@CR56]\].

Acute and chronic hypoperfusion {#Sec8}
-------------------------------

A mechanistic link between hypotension and CI, mediated via chronic cerebral hypoperfusion and loss of the normal autoregulation of cerebral perfusion pressures, has been postulated. Many diseases, including diabetes mellitus and depression, are associated with impaired reactivity of cerebrovascular perfusion autoregulatory systems and this state seems to confer a higher risk of cognitive decline \[[@CR57]\]. HF patients often have systemic hypotension and in the context of disordered autoregulation this could lead to further insults to cerebral perfusion. Cerebral perfusion abnormalities have been demonstrated in HF patients, with reactivity more impaired in patients with greater severity of HF.

These hypoperfusion cognitive problems are not necessarily \'vascular\' dementia. In animal models, reduced cerebral blood flow triggers a neurotoxic cascade that culminates in accumulation of amyloid and hyperphosphorylated tau proteins, the classical precursors of AD. If chronic hypoperfusion is causative, then improving cerebral blood flow should reduce cognitive decline. There is some evidence to support this view in patients with severe HF who have undergone cardiac transplant, pacemaker or cardiac resynchronisation therapy, and in whom measures of cognition have stabilised or improved post-procedure \[[@CR58]\].

Thrombosis and cerebral infarction {#Sec9}
----------------------------------

The potential importance of AF-related cardioembolism has been discussed. Cardioembolism is also seen in HF with sinus rhythm where ventricular function is the most important determinant of thrombus formation and potential embolic cerebral infarction \[[@CR59]\] (Figure [2](#Fig2){ref-type="fig"}). Downregulation of thrombomodulin, structural changes in the cardiac chambers and potential blood stasis in the context of reduced myocardial contractility are associated with thrombus formation that may in turn lead to arterial events of clinical stroke or occult cerebral infarction \[[@CR59]\]. This systemic prothrombotic phenotype increases risk of all thrombo-embolic diseases and HF is also associated with venous thromboembolism \[[@CR60],[@CR61]\]. This is not surprising, as abnormalities in all three constituents of Virchow's Triad (abnormal blood constituents, abnormal vessel wall and abnormal blood flow) are present in HF. Neurohormonal activation seen in HF is associated with increased production of thrombogenic factors such as von Willebrand factor, thromboxane A2 and endothelin. The end result is a hypercoagulable state with increased serum levels of circulating fibrinogen, fibrinopeptide A and D-dimer (amongst others) resulting in platelet and thrombin activation and ultimately leading to plasma hyperviscosity and thrombosis \[[@CR1]\]. A relationship between all these circulating markers of thrombosis and haemostasis and cognitive decline, particularly \'vascular dementia\', has been described \[[@CR62]\]. It would seem intuitive that anticoagulation may prevent sequelae of thrombosis; however, studies of formal anticoagulation in HF with sinus rhythm have been equivocal. To date, no large study of anticoagulation in HF describing cognitive outcomes has been published.Figure 2**Magnetic resonance imaging of brain (diffusion weighted imaging sequences) in a patient with severe left ventricular systolic dysfunction and acute cognitive change.** The initial images were felt to represent a multi-infarct state, presumed cardioembolic and \'watershed\' (hypoperfusion) infarction. Subsequent investigations revealed that the patient had \'shared\' cardiac and cerebral pathology caused by a systemic and cerebral vasculitic process.

Cognitive screening in heart failure services {#Sec10}
=============================================

Given the prevalence and potential impact of CI in HF, a case could be made for routine cognitive screening of HF patients. This is a controversial area with strongly held views on both sides. Recent observational data suggest that informal assessment of cognition by a cardiologist is insufficiently sensitive, with around three in four HF patients with important cognitive problems not recognised as such in routine consultations \[[@CR63]\]. To date, routine screening for CI has not been incorporated into HF clinical guidelines; this may be due in part to the lack of a standardised screening technique that is feasible and acceptable for use in the cardiology outpatient setting. A recent systematic review of cognitive screening questionnaires utilised in HF studies concluded that the accuracy of traditional cognitive assessment measures is questionable in HF populations and appropriate thresholds/normative values need to be established \[[@CR64]\]. In this regard we welcome ongoing work by the Cochrane Dementia and Cognitive Improvement Group to offer synthesis of test accuracy of cognitive assessments in various healthcare contexts \[[@CR65]\].

Treatment implications of cognitive impairment in heart failure {#Sec11}
===============================================================

There is an impressive evidence base to support pharmacological interventions in HF-REF. Historically HF trials have described clinical outcomes such as death, vascular events and hospitalisation with decompensated HF. There has been little focus on cognition or dementia as trial outcome or as a case mix adjuster. In fact for many of the trials that inform the HF evidence base, dementia or CI will have been an exclusion criterion. Where trialists have attempted to describe cognitive effects of HF treatment, results have been neutral \[[@CR30]\].

Central to the treatment of HF is relatively complex multi-drug pharmacological treatment with attendant need for careful biochemical surveillance and self- monitoring. To achieve optimal outcomes requires strict adherence to prescribed evidence-based therapy \[[@CR2]\]. Poor adherence is linked to an elevated risk of hospitalisation and death, whereas appropriate self-management may reduce these risks \[[@CR2]\]. It seems intuitive that ensuring adherence and self-management would be especially challenging in the context of CI.

Interventions with angiotensin converting enzyme inhibitors (ACE-is), which have effects on the renin-angiotensin-aldosterone system (RAAS), have been a mainstay of HF-REF therapy for decades. ACE is also important in neurotransmitter modulation and there are theoretical reasons to believe that ACE-is may have an effect on cognitive decline. Cognitive sub-studies of the Cardiovascular Health Study and the Italian Longitudinal Study on Ageing \[[@CR66],[@CR67]\] both reported that subjects treated with ACE-is had equivalent rates of incident dementia compared with those treated with other antihypertensives. However, there were intriguing within-class differences in cognitive outcomes - for example, between centrally and non-centrally active agents and between differing drug potencies \[[@CR67]\]. The other pillars of HF-REF therapy, beta-blockers and mineralocorticoid receptor antagonists, may also influence cognition. Although no studies specific to HF are available, there is hypertension literature suggesting theoretical cognitive effects of beta-blockade but inconclusive evidence that this is clinically important \[[@CR68]\]. Cognitive effects of mineralocorticoid receptor antagonists have been demonstrated in animal models but human data are limited \[[@CR69]\].

Novel approaches to pharmacological intervention in HF are being developed, with the natriuretic peptide system a key therapeutic target. These peptides possess differing degrees of haemodynamic, neurohormonal, renal and cardiac effects which may be favourable in the HF setting and may augment the effects of RAAS blockade. Preliminary studies using inhibitors of neprilysin (also known as neutral endopeptidase), an enzyme involved in the breakdown of endogenous natriuretic peptides, have yielded encouraging results \[[@CR70]\]. Based on this experience a phase III trial comparing the angiotensin receptor neprilysin inhibitor molecule LCZ696 to the ACE-i enalapril was undertaken in chronic HF-REF (PARADIGM-HF). This trial was recently stopped for benefit of LCZ696 over enalapril \[[@CR71]\]. However, cardiac optimism must be tempered by caution regarding potential non-cardiac, cognitive adverse effects. Mutations in the neprilysin gene have been associated with familial forms of AD and neprilysin-deficient mice show an AD phenotype \[[@CR72]\].

In the light of non-definitive data, how should we treat a patient with HF and CI? Cognitive enhancing medication such as acetylcholinesterase inhibitors have recognised effects on the cardiac conduction system, occasionally causing bradycardia, sick sinus syndrome or other arrhythmias (including torsades de pointes) resulting from QT prolongation through excessive cholinergic stimulation. One recent study showed donepezil to be safe in patients without symptomatic heart disease and actually reduced levels of plasma brain natriuretic peptide in patients with subclinical HF \[[@CR73]\].

Although there are no data to suggest cognitive benefits of standard HF therapy, there are equally no signals of harm. Given the beneficial effects of pharmacological therapy on mortality and hospitalisation, it would seem sensible to consider these evidence-based medical interventions for all HF patients, tailoring the intervention to suit the patient. A multidisciplinary approach with frequent review and medication titration seems to work well. Prescribers need to be alert to the potential effects of CI on concordance with sometimes complex drug regimens. Early use of compliance aids and involvement of family or carers may help in this regard. The goal of management of HF is to provide \'seamless care\' in both the community and hospital to ensure the treatment of every patient is optimal. Despite the plethora of publications and guidelines, the data consistently show a lower uptake of evidence-based investigations and therapies in older patients with consequent higher rates of HF hospitalizations and mortality \[[@CR43]\]. The current shift away from concentration on individual drug therapies to a focus on systems of care that allow effective treatment delivery is welcomed.

Conclusion {#Sec12}
==========

Recurrent themes in our synthesis of the literature regarding CI and HF are a lack of primary data, methodological limitations in available research, and conflicting results. To progress our understanding we recommend increasing use of cognitive assessment using standardised screening tools in all future HF studies. Although we found numerous studies assessing prevalence, there is a dearth of studies investigating the incidence of CI in HF. Once the incidence and prevalence of CI in HF are better defined we need to evaluate the consequences of CI in HF. Identifying underlying mechanisms for CI in HF may present targets for intervention, the \'holy grail\' of cognitive research. A number of processes have been postulated, and we now need confirmatory studies using new developments in neuroimaging and biomarkers in representative populations of HF patients. All of this will require a multidisciplinary approach between HF and dementia research teams. Such collaborative activity is urgently needed given the projected increases in both CI and HF.

Note {#Sec13}
====

This article is part of a series on *The impact of acute and chronic medical disorders on accelerated cognitive decline'*, edited by Carol Brayne and Daniel Davis. Other articles in this series can be found at <http://alres.com/series/medicaldisorders>.
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